Robert, C., Marquez-Rodas, I., Maio, M., Chiarion-Sileni, V., Rutkowski, P., Eenennaam, H. V., . . . Lassouw-Polman, L. (2023). 770 ADU-1604, a novel CTLA-4 blocking antibody modulates pharmacodynamic markers in PD1 relapse/refractory melanoma patients. BMJ Publishing Group.
Chicago Style (17th ed.) CitationRobert, Caroline, et al. 770 ADU-1604, a Novel CTLA-4 Blocking Antibody Modulates Pharmacodynamic Markers in PD1 Relapse/refractory Melanoma Patients. BMJ Publishing Group, 2023.
MLA (9th ed.) CitationRobert, Caroline, et al. 770 ADU-1604, a Novel CTLA-4 Blocking Antibody Modulates Pharmacodynamic Markers in PD1 Relapse/refractory Melanoma Patients. BMJ Publishing Group, 2023.
Warning: These citations may not always be 100% accurate.